Key Takeaways
- ISRG shares plummeted over 10% to $360.50 on Friday, marking the worst daily decline since April 2022
- Second-quarter EPS of $2.80 exceeded the $2.50 consensus; revenue of $2.89B topped the $2.82B forecast
- Domestic da Vinci procedure expansion decelerated to 12%, falling short of Wall Street’s 13% projection
- Company maintained its full-year outlook, forecasting growth around the midpoint of 13.5%–15.5%
- Johnson & Johnson’s competing Ottova surgical system is expected to receive regulatory approval by late 2026
Intuitive Surgical delivered quarterly results that surpassed analyst expectations across the board, yet investors sent the stock into a tailspin. ISRG shares plummeted more than 10% to close at $360.50 on Friday — the sharpest one-day decline in over two years and the lowest closing price since January 2024, according to Dow Jones Market Data.
Intuitive Surgical, Inc., ISRG
The company’s financial performance appeared robust at first glance. Adjusted earnings per share reached $2.80, comfortably surpassing the $2.50 Street consensus. Total revenue climbed to $2.89 billion, exceeding analysts’ $2.82 billion projection.
Yet the market response was decidedly negative. The culprit? Decelerating procedure volumes.
Domestic da Vinci surgical procedure volumes expanded by 12% during the second quarter, falling short of the 13% growth rate analysts had anticipated and representing a slowdown from the 14% expansion recorded in the first quarter. On a worldwide basis, da Vinci procedures increased 15% compared to the prior-year period.
Company executives attributed the softer numbers to patients delaying non-urgent surgical interventions due to escalating insurance premiums, while others are opting for pharmaceutical alternatives like Ozempic instead of surgical solutions. Management emphasized that medically essential procedures remained resilient.
Despite exceeding quarterly expectations, Intuitive maintained its existing full-year guidance — anticipating global da Vinci procedure growth near the center of its 13.5% to 15.5% forecast range. Market participants had anticipated an upward revision following management’s guidance increase in the previous quarter.
The medical robotics leader also elevated its 2026 adjusted gross profit margin projection to 68%–69% of revenue, an improvement from the previous 67.5%–68.5% target.
What RBC Is Saying
RBC Capital Markets analyst Shagun Singh challenged the market’s negative interpretation of the results. She maintained her Outperform rating on ISRG with a $575 price objective — slightly reduced from $600 — characterizing the quarterly performance as a “clean beat.”
Singh characterized the domestic procedure deceleration as “transient rather than a structural shift in end-market demand,” emphasizing that postponed cases should eventually materialize. She highlighted that international demand accelerated to 20% year-over-year expansion, with robust performance across European, Asian, and other global markets.
“We remain buyers,” Singh stated.
J&J Enters the Ring
The quarterly report arrived amid intensifying competitive pressures. Johnson & Johnson is advancing its proprietary surgical robot, the Ottova, engineered for soft-tissue operations in the upper abdominal region.
J&J anticipates securing regulatory authorization by the conclusion of 2026. This development represents a direct challenge to Intuitive’s commanding market leadership, despite the company currently facing no approved competitor of comparable scale.
HCA Healthcare reported weaker surgical procedure volumes and an uptick in uninsured patient populations earlier this week, providing additional industry context. The expiration of pandemic-era Affordable Care Act subsidies has prompted more Americans to discontinue coverage — a macroeconomic challenge Intuitive’s leadership team acknowledged.
Intuitive’s revised gross margin guidance of 68%–69% for 2026 represents the company’s most recent financial projection for that metric.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
